[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100423472":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":62,"collaborators":64,"id":67,"slug":7,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":7,"maxAge":74,"enrollmentInfo":75,"targetDuration":78,"studyType":79,"phases":7,"briefSummary":80,"conditions":81,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"French Africa Pediatric Oncology Group","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Ndella Ms DIOUF, MD","CONTACT","00(221)77 656 49 13.","ndella.diouf@gfaop.org",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"BRENDA Ms MALLON, MSc","0033142115411","brenda.mallon@gustaveroussy.fr",[19,34,48],{"facility":20,"status":21,"city":22,"state":7,"zip":7,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"CHU de Treichville à ABIDJAN","RECRUITING","Abidjan","Côte d’Ivoire",{"type":25,"coordinates":26},"Point",[27,28],-4.00167,5.35444,{"lat":28,"lon":27},[31],{"name":32,"role":11,"phone":7,"phoneExt":7,"email":33},"LINE COUITCHERE, DOCTOR","line.couitchere@gfaop.org",{"facility":35,"status":21,"city":36,"state":7,"zip":7,"country":37,"cosmosGeoPoint":38,"geoPoint":42,"contacts":43},"CHU Donka 030 BP 554","Conakry","Guinea",{"type":25,"coordinates":39},[40,41],-13.67729,9.53795,{"lat":41,"lon":40},[44],{"name":45,"role":11,"phone":46,"phoneExt":7,"email":47},"Dr Aïssata BARRY, DR","00(224)622300084","docteumama@gmail.com",{"facility":49,"status":21,"city":50,"state":7,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Hôpital Aristide Le Dantec, Avenue Pasteur,","Dakar","BP 3001","Senegal",{"type":25,"coordinates":54},[55,56],-17.44406,14.6937,{"lat":56,"lon":55},[59],{"name":60,"role":11,"phone":7,"phoneExt":7,"email":61},"NDELLA DIOUF, DOCTOR","ndella61@hotmail.com",{"type":63,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[65],{"name":66,"class":6},"Gustave Roussy, Cancer Campus, Grand Paris","100423472",false,"NCT04794296","Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP","LALGFA2019","Inclusion Criteria:\n\nChildren 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2\n\n\\-\n\nExclusion Criteria:\n\nALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21","ALL","18 Years",{"count":76,"type":77},500,"ESTIMATED","10 Years","OBSERVATIONAL","The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G\u002FL or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.",[82],"Childhood ALL","2026-02-27",{"date":85,"type":86},"2026-03-02","ACTUAL",{"date":88,"type":86},"2021-11-15",{"date":90,"type":77},"2030-12-31",{"name":5,"class":6},3]